Levetiracetam Teva

Levetiracetam, the active ingredient in Levetiracetam Teva, is an anticonvulsant presented as an intravenous solution for intravenous use. It treats epilepsy, including partial‑onset seizures and generalized tonic‑clonic seizures, in patients who require parenteral therapy.

GNH USA supplies Levetiracetam Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug used to control seizure activity across several epilepsy syndromes.

Partial‑onset seizures: reduces seizure frequency in patients with focal epilepsy. Generalized tonic‑clonic seizures: helps control convulsive episodes in generalized epilepsy. Epilepsy (overall): provides adjunctive therapy for patients with refractory seizures.

Levetiracetam may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Fatigue - Dizziness - Somnolence - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Severe depression or suicidal thoughts - Respiratory depression (rare) - Hepatic failure (very rare)

When prescribing levetiracetam, clinicians should consider several safety aspects. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic dysfunction: monitor liver enzymes regularly. - Psychiatric symptoms: observe for mood changes, depression, or suicidal ideation. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy and lactation: risk unknown; weigh benefits against potential fetal exposure. - Store at room temperature: keep in original container, protect from light and moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may lower levetiracetam plasma concentrations. - Enzyme‑inducing antiepileptics (phenytoin, phenobarbital): can reduce therapeutic effect. - Strong CYP3A4 inhibitors: potential increase in levetiracetam levels, requiring monitoring.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression. - Valproate: may require dose adjustment of levetiracetam. - Aminoglycoside antibiotics: competition for renal excretion pathways.